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Introduction: Amplification of fibroblast growth factor recep-
tor 1 (FGFR1) has been reported in squamous cell lung car-
cinoma and may be a molecular target for therapy. Little is 
known, however, about the clinical and demographic corre-
lates of FGFR1 amplification.
Methods: The study is an Institutional Review Board approved 
retrospective analysis of 226 patients with squamous cell 
lung cancer seen at the Massachusetts General Hospital from 
2005 to 2011. Clinical and demographic characteristics of all 
patients were obtained, as well as treatment details including 
surgery, radiation, and chemotherapy, and overall survival. 
fluorescence in situ hybridization was performed for FGFR1 
on formalin-fixed paraffin-embedded tumor tissue. Clinical 
genotyping results were also reviewed where available.
Results: Thirty-seven of 226 patients (16%) with squamous 
cell lung cancer were found positive for amplification using 
a definition of amplification of a gene to copy number con-
trol ratio of 2.2 or higher. FGFR1 amplification status was 
not associated with age, sex, stage, histologic subtype within 
squamous cell, smoking history, or pack-years of smoking. We 
found no significant difference in overall survival by FGFR1 
amplification status as a whole; in the advanced stage subset, 
our findings are inconclusive because of the small sample size.
Conclusion: FGFR1 amplification was found in 16% of a clini-
cal cohort of squamous cell lung cancer patients. The lack of 
any specific clinicodemographic features that correlates with 
FGFR1 amplification suggests that all squamous cell patients 
should be tested for this genomic change.
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Lung cancer is the leading cause of cancer-related death in the United States, with over 220,000 new cases and over 
157,000 deaths annually.1 Approximately 85% of newly diag-
nosed lung cancers are non–small-cell lung cancer (NSCLC), 
and of these, approximately 30% are squamous cell carci-
noma. Squamous cell carcinoma and adenocarcinoma of the 
lung are increasingly recognized as harboring different molec-
ular profiles2,3 and requiring different treatment strategies.4–9 
In adenocarcinoma, effective molecularly targeted therapies 
such as erlotinib and crizotinib have dramatically improved 
the clinical course for patients with sensitizing epidermal 
growth factor receptor (EGFR) mutations and anaplastic lym-
phoma kinase (ALK) translocations.10–15 Further progress in 
NSCLC treatment will require the identification and success-
ful targeting of molecular alterations in all subtypes of lung 
cancer, including squamous cell.
One potential molecular target in squamous cell lung 
cancer is fibroblast growth factor receptor 1 (FGFR1). 
Amplification at 8p12 was observed in multiple studies of 
squamous cell lung cancer,16–18 and FGFR1 has been identi-
fied as a potential candidate gene in this region. FGFR1 is 
a member of the FGFR family of receptor tyrosine kinases; 
activation leads to downstream signaling via the phosphati-
dylinositol 3-kinase/v-akt murine thymoma viral oncogene 
homolog 1 (PI3K/AKT)/reticular activating system/mitogen 
activated protein kinase (RAS/MAPK) pathways, which 
are central to growth, survival migration, and angiogenesis 
in many cancers. Dysregulation of FGFR family signal-
ing has been described in multiple cancers, with amplifi-
cation, translocation, and point mutations being described 
in a broad range of tumor types including breast, pros-
tate, myeloma, sarcoma, bladder, and endometrial cancers, 
among others.19–23
In lung cancer, FGFR1 amplification is found in 
approximately 20% of squamous cell cancers, but rarely in 
adenocarcinoma.17 Inhibition of FGFR1 in amplified cell lines 
and in mouse models with FGFR1-amplified engrafted tumors 
showed growth inhibition and induced apoptosis.17 Multiple 
FGFR inhibitors are in development; many of these are 
multitargeted tyrosine kinase inhibitors with activity against 
other targets in addition to FGFR1.
Other than the association with squamous histology, little 
is known about clinical or demographic correlates of FGFR1 
amplification. In this study we describe the rate of FGFR1 
amplification, colocalization with other potential oncogenic 
changes, and clinical and demographic correlates, in our cohort 
of squamous cell lung cancer patients.
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MATERIALS AND METHODS
Patient Population
The study is an Institutional Review Board approved ret-
rospective analysis of 226 patients with squamous cell lung 
cancer seen at the Massachusetts General Hospital from 2005 
to 2011. For all patients, medical records were reviewed to 
obtain clinical and demographic characteristics, including age, 
sex, stage, histology, smoking history, treatment details includ-
ing surgery, radiation, and chemotherapy, and overall survival. 
In addition, clinical genotyping results were reviewed. Since 
2009, molecular testing of tumors for genomic changes has 
been integrated into the Massachusetts General Hospital 
oncology clinic as a part of standard clinical care.2 We employ 
the SNaPshot platform, a validated, Clinical Laboratory 
Improvement Amendments-certified, multiplex tumor-geno-
typing assay that uses formalin-fixed paraffin-embedded 
tissue to identify commonly mutated loci in many key onco-
genes.2,24,25 fluorescence in situ hybridization (FISH) has been 
routinely performed for ALK in adenocarcinoma cases since 
2009 for FGFR1 and platelet derived growth factor receptor A 
(PDGFRA) in squamous cell carcinoma since 2011.
In this cohort we reviewed all patients with squamous 
cell lung cancer seen during the study period and included 
those who have been prospectively genotyped as part of their 
clinical care as well as those with available tissue blocks for 
retrospective analysis of FGFR1 amplification by FISH.
FISH for FGFR1 and PDGFR
Hematoxylin and eosin staining was performed on 5-μm 
sections from formalin-fixed paraffin-embedded tumor tissue 
and areas for hybridization marked with a diamond-tipped pen. 
Formalin-fixed paraffin-embedded slides were deparaffinized, 
treated with protease, and co-denatured with FISH probes using 
a Hybrite slide processor (Abbott Molecular, Abbott Park, IL), 
washed, counterstained, cover-slipped, and analyzed using an 
Olympus BX61 fluorescence microscope (Olympus, Center 
Valley, PA) equipped with orange, green, and 4’,6-diamidino-
2-phenylindole filters. Images were captured and analyzed 
using Cytovision software (Genetix Inc., San Jose, CA). Positive 
cases were defined as tumors harboring a gene:copy number 
control ratio 2.2 or higher.26 The bacterial artificial chromosome 
clone CTD-2288L6 (chromosome 8p FGFR1 locus labeled 
orange; Invitrogen, Carlsbad, CA) was paired with a centromere 
8 copy number control (CEP8 SpectrumAqua, Abbott-Vysis 
06J54-018). Bacterial artificial chromosome clone RP11-58C6 
(chromosome 4q12 PDGFRA locus labeled orange; Invitrogen, 
Carlsbad, CA) was paired with a centromere 4 copy number 
control (CEP4 SpectrumGreen, Abbott-Vysis 06J37-014).
Statistical Considerations
Demographic and clinical information were compared 
across tumor genotypes using Pearson χ2 tests (for categorical 
variables) and Kruskal-Wallis tests (for continuous variables), 
where appropriate. Standard methods for time-to-event data, such 
as Kaplan–Meier methods and log rank test were used to compare 
survival outcomes by genotype. All statistical testing was done 
using SAS software version 9.3 (SAS Institute, Cary, NC).
FIGURE 1.  FGFR amplification. FISH analysis of FGFR1 dem-
onstrates FGFR1 gene amplification in this tumor. Amplified 
FGFR1 appears as a cluster of isolated red signals; note 
that this is present in some and not all tumor cells. FGFR1, 
fibroblast growth factor receptor 1; FISH, fluorescence in situ 
hybridization.
TABLE 1.  Patient Characteristics
Total FGFR1 Amp FGFR Not Amp
N = 226 n = 37 n = 189 p
Age, yrs (median, range) 69 (38–91) 67 (39–87) 69 (38–91) 0.53
Sex 0.14
Male 128 (57%) 25 (68%) 103 (55%)
Female 98 (43%) 12 (32%) 86 (45%)
Histology 0.77
Squamous 200 (89%) 33 (89%) 167 (89%)
Sq uamous with 
basaloid
17 (8%) 3 (8%) 14 (7%)
Sq uamous with  
small cell
3 (1%) 0 3 (2%)
Sq uamous with  
clear cell
3 (1%) 1 (3%) 2 (1%)
Sq uamous with focal 
adeno component
3 (1%) 0 3 (1%)
Stage 0.39
1A 57 (25%) 10 (27%) 47 (25%)
1B 54 (24%) 6 (16%) 48 (25%)
2A 19 (8%) 6 (16%) 13 (7%)
2B 25 (11%) 5 (14%) 20 (11%)
3A 34 (15%) 6 (16%) 28 (15%)
3B 10 (4%) 2 (5%) 8 (4%)
4 27 (12%) 2 (5%) 25 (13%)
Smoking status 0.76
Never smoker 9 (4%) 2 (5%) 7 (4%)
Former smoker 172 (76%) 29 (78%) 143 (76%)
Current smoker 45 (20%) 6 (16%) 39 (20%)
Pa ck-yrs  
(median, range)
50 (0–180) 53 (0–162) 50 (0–180) 0.79
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RESULTS
A total of 226 patients with squamous cell lung cancer 
were analyzed for FGFR1 amplification and 37 (16%) were 
positive for amplification using a definition of amplification 
of a gene to copy number control ratio 2.2 or higher. Figure 1 
shows a representative image of a tumor with FGFR1 ampli-
fication. FGFR1 amplification was a focal event, involving 
only a subset of tumor cells, in the majority (> two thirds) of 
the positive cases, in accordance with prior reports.17 Table 1 
depicts basic demographic and clinical features of the cohort. 
FGFR1 amplification status was not associated with age, sex, 
stage, histologic subtype within squamous cell, smoking his-
tory, or pack-years of smoking.
Of the 37 patients who were FGFR1 amplified, 18 also 
had clinical genotyping performed with SNaPshot. Three of 
18 cases had p53 mutations and one had a PIK3CA muta-
tion. It should be noted that the SNaPshot platform under-
estimates alterations in p53 as it tests for hotspot mutations 
only. Overall, 130 squamous cell lung cancer patients from 
the cohort had clinical genotyping performed via SNaPshot. 
Just as in the FGFR1-amplified group, the most common 
abnormality seen in the overall group was p53 mutation (n 
= 14), followed by PIK3CA mutation (n = 12). Two patients 
had KRAS mutations; both these cases were squamous his-
tology (p63+, TTF1−), with focal adenocarcinoma compo-
nent on histology. PDGFRA amplification was also tested 
and found in seven of 160 cases (4%), including two patients 
who had both FGFR1 and PDGFRA amplification. Figure 
2 depicts the distribution of genotype findings in squamous 
cell carcinoma.
There were no statistically significant differences in 
overall survival by FGFR1 status in the population as a whole 
(log rank p = 0.36, see Table 2 and Fig. 3A). This held true 
for those with stage I and II squamous cell lung cancer, the 
vast majority of whom were treated with primary surgical 
resection (Fig. 3B). Although patients with advanced stage 
(stages 3–4) squamous cell lung cancer seemed to do better if 
FGFR1 amplified, the sample size is small and has a moderate 
rate of censoring, rendering definite conclusions from 
this observation challenging. We attempted to account for 
treatment heterogeneity among the group by including only 
those with advanced disease treated with primary platinum-
doublet–based chemoradiation or chemotherapy, and observed 
a similar trend, though again conclusions are limited because 
of lack of power.
DISCUSSION
We have reported the findings from a North American 
single-center series of squamous cell lung cancer patients 
undergoing molecular genotyping and identified a 16% rate of 
FGFR1 amplification. Contrary to other molecular changes in 
lung cancer, such as EGFR mutations or ALK translocations, 
we did not find a distinct pattern of clinical characteristics that 
could help identify those likely to harbor FGFR1 amplification. 
There was no correlation with age or sex. In terms of smoking 
history, Weiss et al.17 had previously reported that they had 
found FGFR1 amplification only in smokers, and not in never 
smokers. Although the majority of patients with squamous 
lung cancer are former or current smokers, in our cohort of 
patients there was a small proportion that comprised never 
smokers, and FGFR1 amplification was found among this 
group and in those with a smoking history.
Similar to Weiss et al.,17 we found concurrent p53 
mutations among our patients who had FGFR1 amplification. 
The observed frequency of p53 in our cohort is likely 
an underestimate of true p53 alterations because of the 
limitations of the SNaPshot assay, which focuses on hotspot 
mutations only whereas a large proportion of p53 alterations 
are known to occur at other loci. We also found co-occurrence 
of FGFR1 amplification with other tumor genetic alterations, 
including PIK3CA mutation and PDGFRA amplification. As 
would be expected in squamous cell lung cancer, we found a 
relatively frequent occurrence of p53 and PI3K mutations in 
our cohort. KRAS mutation was rare and only found in cases 
which were squamous cell carcinoma but exhibited glandular 
differentiation in a small fraction (<10% of tumor cells).
FIGURE 2.  Molecular alterations in squamous cell. Observed 
frequency of p53 in our cohort is likely an underestimate 
of true p53 alterations because of the limitations of the 
SNaPshot assay, which focuses on hotspot mutations.
TABLE 2.  Overall Survival by FGFR1 Amplification
FGFR1 Status Events/Total
Median OS  
(Yrs) (95% CI)
Log Rank  
p
Entire cohort
Amplified 8/37 5.9 (2.7–NR) 0.36
Not amplified 45/189 4.6 (3.7–6.0)
Stage I–II
Amplified 7/27 4.9 (2.7–NR) 0.66
Not amplified 24/128 5.6 (3.8–NR)
Stage III–IV
Amplified 1/10 NR 0.07
Not amplified 21/61 2.5 (1.3–4.6)
Platinum 
chemoRT/chemo
Amplified 0/4 NR 0.09
Not amplified 11/25 1.0 (0.7 – 4.3)
NR, not reached; RT, radiation.
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We found no significant difference in overall survival by 
FGFR1 amplification status. This is contrary to the findings 
of Weiss et al.,17 who reported a trend toward inferior survival 
among those with FGFR1 amplification. Of note, the lack of 
an overall survival difference remains when we stratify our 
population into those with early-stage squamous cell lung 
cancer treated with surgical resection alone; here, without 
the confounding variables of other therapies we are likely to 
have the best assessment of prognostic impact. We find no evi-
dence that FGFR1 amplification is a poor prognostic marker 
in patients with squamous cell lung cancer.
Our finding that FGFR1-amplified patients with 
advanced stage lung cancer treated with platinum-doublet–
based chemoradiation or chemotherapy seemed to have a 
trend toward improved survival should be interpreted cau-
tiously. The sample size in this series is too small to draw 
definitive conclusions, and larger studies or combinations of 
experiences of multiple institutions will be helpful in clarify-
ing whether this is a true association.
It should be noted that FGFR1 amplification has been 
reported to be associated with worse clinical outcomes in other 
cancers. However, it remains unclear whether these studies truly 
reflect an association with poor prognosis or relative endocrine 
resistance. Amplification of 8p12 has been reported in approxi-
mately 10% to 20% of breast cancer.27,28 Multiple studies have 
reported that FGFR1 amplification in breast cancer is associ-
ated with worse metastasis-free survival.28,29 However, FGFR1 
amplification was also found to be associated with resistance 
to endocrine therapy.29 In one of the studies, all the patients 
whose tumors were investigated had received adjuvant tamoxi-
fen; in another, no clinical treatment data is reported, but given 
that the study comprised a majority of estrogen receptor posi-
tive localized breast cancer cases, adjuvant endocrine therapy 
seems likely to have been given in a significant proportion of 
patients. Therefore, it remains unclear whether the worse out-
comes noted were caused by the truly prognostic effects of 
FGFR1 amplification itself, or differences in responsiveness to 
adjuvant endocrine therapy. Interestingly, FGFR1 amplification 
may be associated with antiandrogen resistance as well. In pros-
tate cancer, overexpression of FGFR1 has been associated with 
increased risk of developing castrate-resistant prostate cancer 
when FGFR1 expression is elevated in hormone-naive tumors, 
FIGURE 3. A, Overall survival by FGFR1 amplification status. B, Overall Survival by FGFR1 amplification status in stage 1 to 2. 
FGFR1.
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higher levels in castrate-resistant versus hormone-naive tumors, 
as well as shorter time to death in castrate-resistant tumors.30
Defining therapeutic targets for subgroups of squamous 
cell lung cancer patients is critical to advancing treatment of 
this disease. Currently, FGFR1 amplification defines the larg-
est such subgroup, and efforts to target this population are 
already ongoing with some genotype-specific trials already in 
progress. Whether FGFR1 amplification will be a predictive 
marker for FGFR-targeted therapies remains to be proven. A 
phase 1b trial of BGJ398, an oral pan FGFR kinase inhibitor, 
is underway in patients with advanced solid tumors that har-
bor specific FGFR abnormalities (FGFR1 or FGFR2 amplifi-
cation or FGFR3 mutation). Multiple other FGFR inhibitors 
are in clinical development (see Table 3); many of these are 
multitargeted, frequently hitting other receptors, including 
PDGFR and vascular endothelial growth factor receptor, in 
addition to FGFR, and most current ongoing clinical trials 
are not genotype specific.22,23 Some kinase inhibitors such as 
ponatinib seem to have activity when tested against a vari-
ety of cell lines with either FGFR amplification or mutation.31 
There are also attempts to try to more selectively target FGFR 
while minimizing vascular endothelial growth factor receptor 
effects.32
One noteworthy point is that although we identified 
FGFR1 amplification in 16% of our squamous cell lung can-
cer cases, the amplification level was generally not very high, 
and amplification was focal. The heterogeneity of amplification 
within a tumor sample, where not all tumor cells exhibit FGFR1 
amplification, may suggest that targeting FGFR1 alone may not 
yield adequate tumor regression or control given this focality. 
The results of clinical trials testing FGFR1 inhibitors in ampli-
fied tumors with correlation to level and extent of amplification 
will be critical to understand this issue further.
Our data confirm a robust rate of FGFR1 amplification 
in squamous cell lung cancer patients. Further clinical inves-
tigations to target this molecularly defined subgroup of squa-
mous cell patients will be of great interest. 
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